Gilead Sciences and Yuhan Corporation have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of advanced fibrosis due to nonalcoholic steatohepatitis, according to a press release.
“This collaboration builds on our long-term partnership with Yuhan, with a new focus on the investigation of novel approaches to treat patients with advanced fibrosis due to NASH that complement our ongoing research programs,” John McHutchison, MD, AO, chief scientific officer and head of research and development at Gilead Sciences, said in

Source link